KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials.

Steven R Feldman, Braulio Gomez, Xiangyi Meng, Rebecca Germino

J Dermatolog Treat 32(7) 709-715

PMID31873050
PMCID-
DOI10.1080/09546634.2019.1708854
发表日期2019-12-25
摘要

摘要

BACKGROUND: Patients with psoriasis experience decreased health-related quality of life due to physical and psychological burdens. OBJECTIVE: To assess the effect of a highly effective psoriasis treatment (secukinumab) on domains of the 3-level EuroQol 5 Dimensions questionnaire (EQ-5D-3L) in patients with moderate-to-severe psoriasis who reported problems at baseline. METHODS: This pooled analysis of four phase 3 clinical trials (ERASURE [NCT01365455], FIXTURE [NCT01358578], FEATURE [NCT01555125], and JUNCTURE [NCT01636687]) included patients with moderate-to-severe psoriasis randomized to receive placebo or secukinumab 300 mg and who reported problems in the EQ-5D-3L domains of mobility, self-care, usual activities, pain/discomfort, or anxiety/depression at baseline. Percentage of patients reporting problems in each domain were compared at Weeks 4, 8, and 12 between patients receiving secukinumab 300 mg and placebo. RESULTS: At baseline, 570 patients receiving secukinumab 300 mg and 579 receiving placebo reported ≥1 problem in the EQ-5D-3L domains. Patients receiving secukinumab 300 mg reported improvements in all 5 domains at Weeks 4, 8, and 12 compared with placebo (all p < .0001). CONCLUSION: These findings provide additional evidence of the quality-of-life impairment in patients with moderate-to-severe psoriasis and highlight the improvement across all EQ-5D-3L domains among patients treated with secukinumab.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。